Verseon presents new anticoagulant data
Verseon Corp. has released new data for a promising class of anticoagulants that was presented at the Third International Conference on Heart & Brain (ICHB) in Paris at the end of February. Read More »
Verseon Corp. has released new data for a promising class of anticoagulants that was presented at the Third International Conference on Heart & Brain (ICHB) in Paris at the end of February. Read More »
The American Society of Health-System Pharmacists (ASHP) announced earlier this week that it has published new guidelines for pharmacists who are currently involved with HIV care. Read More »
The U.S. Food and Drug Administration (FDA) recently approved a new indication for the Novartis drug, Afinitor (everolimus). Read More »
Taiho Pharmaceutical announced last week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended LONSURF for the treatment of metastatic colorectal cancer (mCRC) in adults. Read More »
The Generic Pharmaceutical Association (GPhA) and its Biosimilars Council has released a statement from its President and CEO, Chip Davis, commending the International Generic and Biosimilar Medicines Association (IGBA) for persuading the World Health Organization (WHO) to carry out an evaluation of the global impact for the voluntary biologic qualifier (BQ) proposal for the quality, safety and access to biologic products. Read More »
The US Oncology Network has announced the launch of a new groundbreaking program that was developed to aid oncologists from around the country prepare for the execution of the new Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM) and other alternate payment models. Read More »
Robert M. Califf, M.D., will be appointed the new commissioner of the U.S. Food and Drug Administration (FDA) after the Senate recently voted in favor of his appointment, 89-4. Read More »
XYMOGEN announced that it has been awarded a prestigious certification from Australia's Therapeutic Goods Administration (TGA). Read More »
Walgreens has announced, in accordance with its goal to combat drug abuse in the United States, that it has made naloxone available in its Ohio pharmacies without a prescription. Read More »
The American Society of Health-System Pharmacists (ASHP) has announced its 2016 Board of Directors’ Awards recipients. Read More »
Governors and physicians have come together to call for a resolution to the United States’s opioid epidemic. Read More »
McKesson has announced the release of Conserus Imaging Fellow. Read More »
Veloxis Pharmaceuticals has announced the closing of its Horsholm, Denmark office and that it will be relocating to the United States. Read More »
Prime Therapeutics announced last week that it will start the management of pharmacy benefits for Blue Cross & Blue Shield of Rhode Island (BCBSRI) beginning on Jan 1, 2017. Read More »
Pfizer recently published the results to its Phase 3 study of BeneFIX Coagulation Factor IX (recombinant) 100 IU/kg prophylaxis compared to on-demand treatment for patients with moderately severe or severe hemophilia B. Read More »
AstraZeneca and MedImmune have announced that the U.S. Food and Drug Administration (FDA) has granted MEDI-551, an anti-CD19 monoclonal antibody, Orphan Drug Designation. Read More »
Pharmacyclics LLC, an AbbVie company, and Janssen Biotech Inc., developers of the award-winning drug Imbruvica (ibrutinib) aim to continue enhancing the cancer-fighting drug’s clinical meaningfulness. Read More »
Amgen has announced that its supplemental Biologics License Application (sBLA) for the extended use of Enbrel (etanercept) in the treatment of chronic severe plaque psoriasis in pediatric patients has been accepted for review by the U.S. Food and Drug Administration (FDA). Read More »
Pfizer today released its 2015 integrated annual review, which is an in-depth look at the company’s financial, social and environmental performance. Read More »
Sanofi and Regeneron Pharmaceuticals announced that the Phase 3 study of monotherapies set to demonstrate the superiority of sarilumab to adalimumab when treating active rheumatoid arthritis (RA) has met its primary goal. Read More »